An anti-centromere antibody result can be a meaningful clue to limited systemic sclerosis, particularly with Raynaud’s and a centromere ANA pattern. It is not, by itself, a diagnosis or a forecast of how someone will feel.
- Anti-centromere antibody supports limited systemic sclerosis when paired with clinical features, but it cannot confirm the diagnosis alone.
- Centromere pattern ANA usually appears as 40–60 discrete nuclear dots on HEp-2 cells during indirect immunofluorescence.
- ACR/EULAR classification assigns anti-centromere antibody 3 points; a total score of 9 or more classifies systemic sclerosis for research purposes.
- Рейноэ феномени that begins after age 30, causes fingertip pits, or accompanies puffy fingers deserves rheumatology assessment.
- Nailfold capillaroscopy can identify giant capillaries, capillary loss, and microhaemorrhages that make an antibody result more clinically persuasive.
- Pulmonary hypertension screening commonly includes yearly echocardiography, pulmonary function tests with DLCO, and NT-proBNP in established systemic sclerosis.
- A positive result may precede definite systemic sclerosis by years, but some people never develop classifiable disease.
- Normal ESR or CRP does not exclude limited systemic sclerosis; these inflammatory markers are often normal in this condition.
What an Anti-Centromere Antibody Result Actually Tells You
An anti-centromere antibody positive result supports an autoimmune connective-tissue process, especially limited systemic sclerosis, but it does not establish the diagnosis by itself. The result becomes far more meaningful when a person also has Raynaud’s phenomenon, puffy fingers, abnormal nailfold capillaries, or skin thickening. As of September 19, 2026, this remains one of the clearest examples of a laboratory clue that needs a careful clinical examination beside it.
The anti-centromere antibody targets proteins at the centromere, the chromosome region that guides orderly cell division. Most clinical laboratories report it as a positive or negative antigen-specific assay, while the screening ANA may show a distinctive centromere pattern. The test does not measure how active systemic sclerosis is, and a higher numerical value on one manufacturer’s assay cannot reliably be compared with another laboratory’s value.
In my clinical work, the most anxious calls often come from people with a positive result and no symptoms at all. That situation needs perspective: the antibody can predate symptoms, but its positive predictive value depends heavily on why testing was ordered in the first place. A person referred for cold-triggered white-blue fingers has a very different pre-test probability than someone tested during a broad wellness panel.
Dr. Thomas Klein’s practical rule is simple: treat the result as a reason to look more carefully, not as a label to apply overnight. A clear explanation of what a positive antibody result means can prevent the common mistake of equating autoantibody positivity with organ damage.
How the Centromere Pattern ANA and Specific Antibody Fit Together
A centromere pattern ANA is a microscope pattern, whereas an anti-centromere antibody is a more targeted antibody result. They often travel together, yet neither result is interchangeable with a clinical diagnosis.
Indirect immunofluorescence on HEp-2 cells is still valuable because it preserves pattern information that a multiplex screen may miss. A classic centromere pattern shows numerous evenly spaced dots in interphase nuclei and bright alignment at metaphase; experienced readers often describe roughly 40–60 dots, reflecting human chromosome centromeres. Laboratories differ in reporting language, so the actual ANA method and titre matter.
An ANA titre of 1:80 is the entry criterion for the 2013 ACR/EULAR systemic sclerosis classification framework, but an ANA titre alone is nonspecific. The same framework awards 3 points for anti-centromere, anti-topoisomerase I, or anti-RNA polymerase III antibodies; classification requires 9 points or more (van den Hoogen et al., 2013). That score is designed for consistent research cohorts, not a substitute for a specialist’s diagnosis.
Кантести - бул AI кан анализи анализатору that reads an ANA and extractable nuclear antigen result in the context of the source laboratory, assay method, and accompanying results rather than treating a single flag as a verdict. Our ANA натыйжасы боюнча колдонмону караңыз explains why pattern, titre, and symptoms should be recorded together.
Why a negative ANA does not always end the discussion
A negative ANA makes classic anti-centromere-associated systemic sclerosis less likely, but assay design can create discordant results. If the clinical picture is compelling, rheumatologists may repeat testing with indirect immunofluorescence or review the original report rather than ordering indiscriminate panels.
Why This Antibody Is Linked With Limited Systemic Sclerosis
Anti-centromere antibody is most strongly associated with limited cutaneous systemic sclerosis, a form in which skin involvement usually stays distal to the elbows and knees and may involve the face. It is associated with a tendency toward later vascular complications, not a guarantee that they will occur.
Limited systemic sclerosis often unfolds slowly. Raynaud’s phenomenon may appear 5–10 years before more recognizable skin changes, which is why a person can be antibody-positive yet not meet classification criteria today. Puffy fingers, tightened skin over the fingers, fingertip depressions, telangiectasia, and reflux are more informative than fatigue or a mildly raised inflammatory marker.
Anti-centromere positivity is generally linked with a lower frequency of early diffuse skin progression and severe early interstitial lung disease than anti-topoisomerase I positivity. The trade-off is a longer-term association with pulmonary arterial hypertension, especially after years of established disease. This is risk stratification, not destiny; age, DLCO trend, echocardiography, and symptoms all modify the picture.
CREST is an older shorthand for calcinosis, Raynaud’s, oesophageal dysmotility, sclerodactyly, and telangiectasia. Few patients arrive with all five features, and I avoid using CREST as a checklist that delays care. The cold hands and feet work-up is a useful starting point when Raynaud’s is the first clue.
Symptoms That Make a Positive Result More Concerning
A positive anti-centromere antibody matters most when it occurs with objective vascular, skin, digestive, or breathing features. Raynaud’s plus puffy fingers or abnormal capillaries carries substantially more weight than Raynaud’s alone.
Primary Raynaud’s typically starts in adolescence or early adulthood, is symmetric, and does not cause ulcers, pits, or lasting tissue changes. Secondary Raynaud’s is more concerning when it begins after age 30, attacks are severe or asymmetric, or fingertips develop scars, pitting, or persistent numbness. Smoking and stimulant medicines can worsen attacks, but they do not explain a systemic sclerosis pattern by themselves.
Shortness of breath on stairs, reduced exercise tolerance, new ankle swelling, chest pressure, or near-fainting should not be blamed automatically on anxiety in someone with established systemic sclerosis. A fall in DLCO to below 60% predicted, particularly with a falling FVC/DLCO ratio pattern, can be an early pulmonary vascular clue and usually triggers specialist review. Breathlessness also has common alternatives—anaemia, asthma, deconditioning, and heart disease—so testing needs breadth.
Reflux that persists despite routine measures, food sticking behind the breastbone, early satiety, and recurrent aspiration-type cough can reflect oesophageal dysmotility. Meanwhile, dry eyes and dry mouth point clinicians toward overlap disease such as Sjögren syndrome, explored in our dryness and Sjögren overview.
What an Anti-Centromere Antibody Positive Test Cannot Prove
An anti-centromere antibody positive test cannot prove that you have systemic sclerosis, predict an exact timeline, or show whether your lungs or heart are affected. It is an immunological marker, not an organ-function test.
A positive anti-centromere result can occur in people with primary biliary cholangitis, Sjögren syndrome, lupus-spectrum illness, other autoimmune conditions, and occasionally no diagnosable rheumatic disease. In primary biliary cholangitis, abnormal alkaline phosphatase and anti-mitochondrial antibody are often more diagnostically useful than centromere antibodies. Our guide to positive anti-mitochondrial antibodies describes that distinct liver-focused pathway.
The antibody also cannot explain every symptom. Widespread muscle pain with normal examination and normal creatine kinase may have a different cause; severe weakness with CK above roughly же рабдомиолиз үчүн жогорку чектен 5 эсе көп болгондо анын кеңири клиникалык колдонулушун сүрөттөгөн. Бул сан сыйкырдуу эмес; CK needs a more urgent muscle-focused assessment. Similarly, a normal ESR and CRP do not rule out systemic sclerosis because many people with limited disease have both values within the laboratory interval.
Kantesti AI — бул AI кан анализинин жыйынтыгы платформасы built to flag discordance—for example, a centromere result paired with cholestatic liver enzymes or unexpected kidney findings—so the next question is clinically sensible. It cannot diagnose systemic sclerosis and should never replace a rheumatology examination.
Nailfold Capillaroscopy: The Follow-Up Test With Real Diagnostic Weight
Nailfold capillaroscopy is one of the most useful next tests when anti-centromere antibody and Raynaud’s occur together. Giant capillaries, capillary haemorrhages, loss of capillary density, and abnormal architecture support secondary Raynaud’s and systemic sclerosis-spectrum disease.
The examination is non-invasive: a clinician places immersion oil on the nailfold and examines capillaries with dermatoscopy or videocapillaroscopy. In healthy adults, density is often around 7–10 capillaries per millimetre; systemic sclerosis patterns can show giant loops, areas of dropout, and disorganised regrowth. One imperfect image is not enough, because trauma from manicures, biting, or manual work can distort a nailfold.
A particularly useful clinical distinction is this: anti-centromere antibody plus Raynaud’s plus a clearly scleroderma-pattern capillaroscopy result deserves structured surveillance even if skin thickening is absent. The VEDOSS approach uses Raynaud’s, ANA positivity, puffy fingers, systemic-sclerosis-specific antibodies, and abnormal capillaroscopy to identify people who may be in a very early disease stage. Progression remains variable.
In my experience, asking patients not to cut cuticles or have a manicure for 2–3 weeks before the study improves image quality more than repeating broad antibody panels. It is also worth documenting a baseline photo of finger swelling for the clinician—subtle change over six months can be more revealing than a single appointment.
Blood and Urine Tests That Shape the Interpretation
Follow-up laboratory testing should look for overlap disease and silent organ involvement, not merely repeat anti-centromere antibody levels. A focused panel usually includes CBC, creatinine/eGFR, urinalysis, liver enzymes, CK, and selected antibodies based on symptoms.
A CBC can identify anaemia that contributes to breathlessness, while creatinine and urine protein assessment help detect a kidney problem that would be atypical for isolated anti-centromere limited disease. A urine albumin-creatinine ratio below 3 mg/mmol is generally considered normal in UK reporting, though a normal result does not assess pulmonary vascular risk. Persistent protein or blood in urine needs its own diagnostic pathway.
Testing may include anti-topoisomerase I, anti-RNA polymerase III, anti-Ro/SSA, anti-La/SSB, RNP, dsDNA, complements C3/C4, rheumatoid factor, and anti-CCP when the symptoms justify them. Ordering every available antibody without a clinical question produces confusing low-level positives. The C3, C4, and ANA guide helps explain why low complement points toward a different pattern than isolated limited systemic sclerosis.
Кантести - бул AI менен иштеген кан анализин талдоо куралы that can organise these cross-panel findings from uploaded reports, but the ordering clinician decides which tests are medically appropriate. If liver alkaline phosphatase is elevated for more than 6 ай, a hepatology-oriented review may be more useful than another ANA titre.
Why Lung and Heart Screening Matters Even When You Feel Well
People with confirmed systemic sclerosis generally need regular lung and pulmonary hypertension surveillance because symptoms can lag behind early physiological change. Anti-centromere antibody supports the rationale for vigilance but does not identify who has pulmonary hypertension today.
Pulmonary function testing measures FVC and DLCO; a declining DLCO can reflect pulmonary vascular disease, interstitial lung disease, anaemia, or technical variation. In established systemic sclerosis, annual FVC and DLCO testing is common practice, with an earlier repeat if breathlessness changes. A decline in FVC of 10 percentage points predicted is clinically meaningful and warrants timely review.
The DETECT algorithm was developed for systemic sclerosis patients with disease duration over 3 жылда and DLCO below 60% predicted; it combines clinical, laboratory, ECG, and echocardiographic variables to decide who needs right-heart catheterisation. Right-heart catheterisation remains the confirmatory test for pulmonary arterial hypertension, not echocardiography alone. The EULAR 2023 update continues to emphasise organ-directed assessment and treatment in systemic sclerosis (Del Galdo et al., 2024).
A normal echocardiogram is reassuring but cannot permanently close the question. NT-proBNP, often reported in ng/L or pg/mL depending on the lab, becomes more informative when interpreted as a trend alongside DLCO and echo findings; our NT-proBNP explanation covers its many non-scleroderma causes.
When Imaging, Swallowing Tests, and Specialist Assessment Are Needed
High-resolution chest CT, echocardiography, gastrointestinal studies, and specialist examination are selected by symptoms and screening results—not by anti-centromere positivity alone. The right next test depends on which organ system is showing a credible signal.
High-resolution chest CT is the most sensitive test for interstitial lung disease, but it exposes patients to radiation and is not automatically repeated every year. A new crackling sound at lung bases, falling FVC, reduced DLCO, or unexplained breathlessness is a more compelling reason to image than antibody status alone. In limited disease, the likelihood of extensive early fibrosis is lower but not zero.
For persistent swallowing difficulty, clinicians may use barium swallow, upper endoscopy, oesophageal manometry, or pH-impedance testing. Reflux can contribute to dental erosion, chronic cough, and sleep disturbance even without classic heartburn. Food that repeatedly sticks, vomiting blood, black stools, or unintentional weight loss of 5% or more in 6–12 months needs prompt medical assessment rather than self-treatment.
Kantesti AI can help patients assemble the chronology of tests and symptoms before a consultation, especially when reports come from several laboratories. For more detail on how reports are handled and clinically reviewed, see our медициналык валидациялоо ыкмасы.
Conditions That Can Resemble Limited Systemic Sclerosis
Raynaud’s, reflux, dry skin, fatigue, and positive ANA results occur in many conditions, so limited systemic sclerosis has several important mimics. A physical examination and targeted tests separate these possibilities better than antibody repetition.
Primary Raynaud’s is common and often has normal nailfold capillaries and negative disease-specific antibodies. Hypothyroidism, medication effects, nicotine exposure, vibration injury, and haematological disorders can also worsen cold hands. Checking TSH and a CBC is often reasonable, but a normal thyroid result does not explain a centromere ANA pattern.
Lupus is more often associated with anti-dsDNA, low complement, cytopenias, rash, serositis, or kidney findings than with anti-centromere antibody. Sjögren syndrome may coexist with centromere positivity and can feature prominent dryness, neuropathy, dental decay, and parotid swelling. The anti-dsDNA test guide explains why that antibody must be read with complement and urine results.
Eosinophilic fasciitis, diabetic cheiroarthropathy, scleromyxoedema, morphea, and certain occupational exposures can cause skin tightness without classic systemic sclerosis. The distribution matters: systemic sclerosis usually involves the fingers early, whereas morphea commonly forms localised plaques and does not produce the same capillary pattern.
False Positives, Low-Level Results, and Laboratory Limitations
Low-level anti-centromere reactivity and discordant ANA testing require confirmation and clinical correlation because assay methods do not have identical sensitivity or specificity. A result is not “false” simply because someone feels well, but it may not represent systemic sclerosis.
Enzyme immunoassays, line blots, chemiluminescent assays, and indirect immunofluorescence measure related but not identical signals. A borderline antigen-specific result without a corresponding centromere ANA pattern should prompt the laboratory report to be reviewed, particularly when the clinical probability is low. Biotin interference is not a typical cause of centromere antibody positivity, unlike its well-known effect on some hormone immunoassays.
Repeat testing is most useful when the first sample was technically uncertain, symptoms evolve, or results conflict with the clinical picture. Repeating an unequivocally positive anti-centromere result every 3–6 ай usually adds little because antibody titres do not reliably track disease activity. Monitoring organs and symptoms is more valuable than chasing a number.
A useful safeguard is to keep the original report, including method, reference interval, ANA titre, and pattern. Our article on сапаттык жана сандык натыйжалар explains why a numerical signal from one assay should not be treated as a universal disease severity scale.
A Sensible Follow-Up Plan After a Positive Result
A sensible plan after anti-centromere antibody positivity includes rheumatology assessment if symptoms or ANA findings support it, baseline organ screening when systemic sclerosis is suspected, and regular follow-up based on actual risk. There is no universal schedule for asymptomatic people.
For a person with Raynaud’s, puffy fingers, or abnormal capillaroscopy, I would usually expect a baseline examination, blood pressure measurement, urinalysis, creatinine, pulmonary function tests, and echocardiography to be considered by the specialist. Follow-up every 6–12 months is common when there is a clear systemic-sclerosis spectrum picture, but intervals should tighten if symptoms change or tests drift.
For an entirely asymptomatic person with isolated positivity, one thoughtful rheumatology review may be enough to establish whether surveillance is needed. The clinician may decide on a repeat clinical review in 12–24 months rather than serial imaging. This cautious approach prevents both missed early disease and the real harm of overtesting.
Kantesti helps users keep time-stamped laboratory reports and symptom context together across visits. Our уақыт бойынша зертханалық талдау жөніндегі нұсқаулық describes why a verified change from baseline is often more useful than a single isolated result.
What You Can Do While Waiting for Specialist Review
Keeping hands warm, avoiding nicotine, controlling reflux, and documenting attacks can reduce symptom burden while evaluation is underway. These measures do not prevent systemic sclerosis, but they can make Raynaud’s and oesophageal symptoms safer and more manageable.
For Raynaud’s, layered gloves, hand warmers, gradual temperature transitions, and smoking cessation are first-line practical measures. Clinicians may prescribe a calcium-channel blocker such as nifedipine when attacks are frequent or painful; doses vary by country and individual blood pressure, often beginning around 10–30 mg daily in modified-release formulations. Do not borrow medication from someone else, particularly if you have low blood pressure.
For reflux, smaller evening meals, avoiding lying flat for 3 саат after eating, raising the head of the bed, and prescribed acid suppression can help. Over-the-counter supplements marketed as “immune balancing” have no evidence that they lower anti-centromere antibodies, and some can interact with prescribed vasodilators or anticoagulants.
A phone photo of colour change taken during an attack, with the room temperature and duration noted, can be surprisingly useful at a first appointment. If you need help preparing a concise report for your clinician, our кан анализинин кыскача чек-листи offers a structured way to bring the right details.
Warning Signs That Need Urgent Medical Assessment
Chest pain, fainting, rapidly worsening breathlessness, a black or non-healing fingertip, severe headache with high blood pressure, or markedly reduced urine require urgent medical assessment. An anti-centromere result does not make these symptoms less urgent.
Call emergency services for severe chest pain, fainting, blue lips, severe breathlessness at rest, or signs of stroke. New exertional near-fainting in systemic sclerosis can signal pulmonary hypertension or arrhythmia and should not wait for the next routine antibody review. A resting oxygen saturation below 92% is another reason for urgent assessment, though baseline targets differ in chronic lung disease.
A blood pressure of 180/120 мм сын.ба. же андан жогору with headache, visual change, chest symptoms, confusion, or reduced urine is an emergency. Scleroderma renal crisis is less associated with anti-centromere antibody than with anti-RNA polymerase III and diffuse skin disease, but every person with suspected systemic sclerosis should know how to respond to abrupt hypertension.
Dr. Thomas Klein advises patients to record their usual blood pressure before symptoms arise, because a rise from 105/65 to 150/95 mmHg can be clinically meaningful even though it is below an emergency threshold. For kidney warning patterns, review заарадагы белок боюнча гиддерде камтылган with a clinician rather than relying on dipsticks alone.
How to Bring the Result Into a Productive Rheumatology Visit
The most useful rheumatology visit starts with the original laboratory report, a symptom timeline, medication list, and any prior lung or heart tests. This gives the clinician enough context to decide whether the result reflects early systemic sclerosis, overlap disease, or an incidental finding.
Bring the exact ANA titre and pattern, the anti-centromere assay name if shown, dates of Raynaud’s onset, photos of finger changes, family autoimmune history, and any CT, echocardiogram, or pulmonary-function reports. Note whether symptoms began before or after a new medicine, pregnancy, major infection, or occupational cold exposure. Chronology can alter interpretation more than a repeat antibody test.
Useful questions include: Do my nailfold findings look like a systemic sclerosis pattern? Do I need baseline FVC, DLCO, echocardiography, or CT? Which symptom should trigger an earlier call? Ask for your blood-pressure target if you have systemic sclerosis, because recommendations are individual rather than a one-size-fits-all number.
Kantesti’s clinical content is reviewed with support from our Медициналык кеңеш, and our role is to make laboratory reports easier to discuss—not to replace the clinician who examines you. The bottom line is reassuringly nuanced: anti-centromere antibody can be a valuable clue, but your symptoms, capillaries, organs, and follow-up over time determine its real meaning.
Көп берилүүчү суроолор
Оң центромерге каршы антитело склеродерма бар экенимди билдиреби?
A positive anti-centromere antibody does not automatically mean you have systemic sclerosis or scleroderma. It supports limited systemic sclerosis most strongly when Raynaud’s phenomenon, puffy fingers, skin changes, or abnormal nailfold capillaries are also present. In the 2013 ACR/EULAR classification system, anti-centromere antibody contributes 3 points, while 9 or more points are needed for classification. A rheumatologist uses the result with examination findings and organ screening rather than diagnosing from the antibody alone.
What is a centromere pattern ANA?
A centromere pattern ANA is a distinctive indirect immunofluorescence pattern seen on HEp-2 cells, usually with 40–60 discrete dots in each cell nucleus. It commonly corresponds to antibodies against centromere proteins, including CENP-B, and is associated with limited systemic sclerosis. The pattern is a screening clue, not confirmation of a disease, because ANA patterns need clinical context. Laboratories should report the ANA titre, such as 1:80 or 1:320, alongside the pattern and method.
Can anti-centromere antibodies be positive without symptoms?
Yes, anti-centromere antibodies can be detected before symptoms develop, and some people with positive results never develop classifiable systemic sclerosis. The significance depends on the pre-test probability: positivity in someone with Raynaud’s and abnormal capillaries is more meaningful than positivity found incidentally. Repeating the antibody every 3–6 months usually does not predict progression. A baseline clinical assessment and an agreed follow-up interval are generally more useful.
What follow-up tests are recommended after an anti-centromere antibody positive result?
Follow-up commonly includes a rheumatology examination, nailfold capillaroscopy, CBC, creatinine/eGFR, urinalysis, liver enzymes, and selected autoimmune antibodies. If systemic sclerosis is suspected or confirmed, pulmonary function tests with FVC and DLCO plus echocardiography are often obtained as baseline assessments. A DLCO below 60% predicted or a meaningful decline in FVC may trigger additional evaluation. High-resolution chest CT and right-heart catheterisation are reserved for specific clinical or screening concerns.
Does anti-centromere antibody predict pulmonary hypertension?
Anti-centromere antibody is associated with a higher long-term risk of pulmonary arterial hypertension in limited systemic sclerosis, but it cannot diagnose or predict pulmonary hypertension in one individual. Screening uses symptoms, echocardiography, pulmonary function tests, DLCO trends, and sometimes NT-proBNP. The DETECT approach was developed for patients with systemic sclerosis lasting more than 3 years and a DLCO below 60% predicted. Right-heart catheterisation is required to confirm pulmonary arterial hypertension.
Can a positive anti-centromere antibody turn negative?
Anti-centromere antibody results often remain positive for years, although values can vary between assay platforms and laboratories. A change from positive to negative does not reliably prove that autoimmune risk has disappeared, and a higher value does not reliably mean disease is worsening. Clinicians generally follow symptoms, blood pressure, lung function, echocardiography, and examination findings rather than antibody titre. If two laboratories disagree, reviewing the ANA method and repeating a confirmatory assay can be reasonable.
Бүгүн AI менен күчөтүлгөн кан анализин талдоону алыңыз
Дүйнө жүзү боюнча 2 миллиондон ашык колдонуучу Kantestiти заматта, так лабораториялык анализ талдоосу үчүн ишенет. Кан анализиңизди жүктөп, бир нече секунд ичинде 15,000+ биомаркерлеринин комплекстүү чечмелөөсүн алыңыз.
📚 Шилтемеленген изилдөө басылмалары
Кляйн, Т., Митчелл, С., & Вебер, Х. (2026). B терс кан тобу, LDH кан анализи жана ретикулоциттердин саны боюнча колдонмо. Kantesti AI медициналык изилдөө.
Кляйн, Т., Митчелл, С., & Вебер, Х. (2026). Орозодон кийинки ич өткөк, заңдагы кара тактар жана ашказан-ичеги боюнча колдонмо 2026. Kantesti AI медициналык изилдөө.
📖 Тышкы медициналык шилтемелер
Del Galdo F et al. (2024). EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ревматикалык оорулар жылнаамасы.
⚕️ Медициналык эскертүү
Бул макала билим берүү максатында гана жана медициналык кеңеш болуп саналбайт. Диагноз коюу жана дарылоо чечимдери үчүн дайыма квалификациялуу саламаттыкты сактоо адисине кайрылыңыз.
E-E-A-T ишеним сигналдары
Тажрыйба
Дарыгер жетектеген лабораториялык чечмелөө иш процесстерин клиникалык кароо.
Экспертиза
Биомаркерлер клиникалык контекстте кандай жүрөрүнө лабораториялык медицина багыты.
Авторитеттүүлүк
Доктор Томас Клейн жазган, доктор Сара Митчелл жана профессор доктор Ханс Вебер тарабынан каралган.
Ишенимдүүлүк
Тынчсызданууну азайтуу үчүн так кийинки кадамдар менен далилге негизделген чечмелөө.